SIBN · SI-BONE, Inc.

Current Thesis

SI-BONE is a profitability-inflection medtech name with a genuine new growth leg the Smith+Nephew pelvic-trauma distribution deal bolted onto a healthy sacroiliac-joint-fusion core. The income statement is improving: Q1 2026 (reported 2026-05-11) delivered $52.6M revenue (+11.2% YoY), positive adjusted EBITDA, ~79.8% gross margin, and management raised FY2026 guidance to $230–233M. Needham named it a 2026 Top Pick (PT $27, Conviction List). The problem for a momentum book is the tape: at ~$15.50 the stock sits below its 200-day, with the 50-day under the 200-day, ~29% off the $21.89 52-week high and only a few dollars above the $11.48 low. The medtech-device theme may carry an accelerating tag, but this name's price structure is rolled over the value-trap signature, not a setup. The correct stance is to stand aside; SIBN earns a momentum entry only on a reclaim of the 200-day and a higher-low base.

Bull Case

• Q1 2026 (2026-05-11): revenue $52.6M, +11.2% YoY; US +10%, international +33.9%; gross margin 79.8%; net loss narrowed to $4.3M; positive adjusted EBITDA reached.
• FY2026 guide raised to $230–233M (~14–16% YoY), implying second-half reacceleration; gross-margin guide lifted ~100bps to ~79%.
• Smith+Nephew distribution agreement (signed 2026-02-23) puts iFuse TORQ / TORQ TNT into Level 1 & 2 trauma centers nationwide; rollout began March 2026 and ramps across the year a new TAM (pelvic fragility fractures) layered on the SI-joint base.
• iFuse TORQ TNT is the first 3D-printed transiliac-transsacral screw, carries FDA Breakthrough Device status, and qualifies for CMS NTAP reimbursement up to $4,136 per case a concrete hospital adoption incentive.
• Active physician base >1,650, +17% YoY, extending a multi-quarter double-digit growth streak the utilization base is widening.
• Sell-side aligned: Needham 2026 Top Pick / Conviction List, PT $27; consensus ~$25–25.57, Strong Buy, high estimate $32 roughly 60–100% above spot.

Bear Case

• Price structure is broken: below the 200-day SMA, 50-day under the 200-day, ~29% off the 52-week high. Cheap multiples on a rolled-over chart is how value traps look.
• Revenue growth has decelerated to +11.2% this is a mid-teens grower, not a hypergrowth story.
• The FY guide bakes in a second-half reacceleration the tape has not confirmed; if the Smith+Nephew trauma ramp lands slower than modeled, the +14–16% guide is at risk.
• Still GAAP loss-making; the adjusted-EBITDA positivity is early and thin.
• Small/mid-cap medtech with thin float dynamics institutional selling (Two Sigma trimming flagged mid-2025) can overwhelm the fundamental story for quarters at a time.

Setup & Price Structure

Spot ~$15.50 (recent close $15.53), inside a $11.48–$21.89 52-week range the lower-middle third. The stock trades below its 200-day SMA with the 50-day beneath the 200-day, a downtrend configuration with no momentum to ride. The name has spent 2026 grinding lower off the high and now needs to build a base. The upside level that matters is a daily/weekly reclaim of the 200-day, roughly the $17–18 shelf; below, the $14 area is the near-term floor, and losing it opens the path back toward the $11.48 low. For a strength-is-the-setup playbook there is nothing to act on here the entry signal is a reclaim with a higher low, and the chart has produced neither.

Catalyst Calendar (next 30 days)

• 2026-06-16: Truist Securities 2026 MedTech Conference fireside chat (8:40am ET) a visibility event; watch for Smith+Nephew trauma-ramp commentary, but no binary risk attached.
• Q2 2026 earnings: ~early August 2026 (est., outside the 30-day window) the first print to test whether the Smith+Nephew ramp and the guided reacceleration are showing up in numbers. This is the real catalyst.
• No FDA/PDUFA or other dated binary inside the next 30 days.

What Would Change Our Mind

• Bullish flip: a weekly close back above the 200-day (~$17–18) on expanding volume that forms a higher low the momentum confirmation that converts this from value trap into a buyable base; that is the trigger to take a probe.
• Bearish confirmation: a weekly close below $14 heading toward the $11.48 low, confirming the downtrend and keeping the name a pass.
• Fundamental break: Q2 (~early Aug) revenue growth decelerating below ~11% YoY, signaling the Smith+Nephew / pelvic-trauma ramp is not translating into the income statement.

Correlation Notes

• Trades with small/mid-cap spine and ortho medtech (Globus/GMED, NuVasive-type spine peers, the device-recovery cohort) and the broader unprofitable-medtech basket sensitive to rate and risk-appetite swings as a long-duration small cap.
• Partner dependency the chart can't price: Smith+Nephew (SNN) execution on the trauma distribution deal SNN sales-force prioritization is a direct swing factor for the new growth leg.
• Beta to elective-procedure volume and hospital-capex sentiment; reimbursement headlines (CMS NTAP) can move it independent of the tape.